Kane Biotech Inc. KNE.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -81.27% | 307.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -81.27% | 307.24% | |||
| Cost of Revenue | -86.01% | 266.50% | |||
| Gross Profit | 135.71% | -151.85% | |||
| SG&A Expenses | 44.55% | -10.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.65% | 19.68% | |||
| Operating Income | -15.48% | -8.70% | |||
| Income Before Tax | -15.73% | -10.28% | |||
| Income Tax Expenses | -9.68% | 104.00% | |||
| Earnings from Continuing Operations | -15.58% | -32.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.58% | -32.83% | |||
| EBIT | -15.48% | -8.70% | |||
| EBITDA | -16.83% | -8.29% | |||
| EPS Basic | -148.28% | -31.82% | |||
| Normalized Basic EPS | -150.00% | -12.50% | |||
| EPS Diluted | -148.28% | 30.95% | |||
| Normalized Diluted EPS | -150.00% | -12.50% | |||
| Average Basic Shares Outstanding | -54.16% | 0.14% | |||
| Average Diluted Shares Outstanding | -54.16% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||